Abirapro 250mg Tablet
Rx RequiredSalt Composition: Abiraterone Acetate
Expiry Date: 01/2028
Buy at $141.18
Inclusive of all taxes
120 Tablet in Bottle
About The Product
Prostate Cancer
Abirapro is a hormonal anticancer medication containing abiraterone acetate (250 mg). It is used primarily to treat advanced prostate cancer in adult men. It is a steroidal derivative of progesterone for the treatment of patients with hormone-refractory prostate cancer. It may also be used to treat other conditions, as determined by the doctor. It is sometimes used in combination with certain other medicines as part of a chemotherapy regimen. When Abirapro 250mg Tablet is prescribed for an early stage of this disorder, it is used with testosterone-lowering treatment. This medicine is not for use in women or children.
Uses of Abirapro 250mg Tablet
It is used in combination with prednisone or prednisolone and together with androgen-deprivation therapy (ADT) or post-orchiectomy. It is used in adult men for:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Side effects
The human body takes some time to adjust after consuming the medicine. Not every side effect requires medical assistance. If you observe there are serious changes that cannot be handled well by the patient, consult your doctor immediately. Common side effects are mentioned below:
- High blood pressure
- Low potassium
- Liver enzyme elevation
- Fluid retention
- Fatigue
- Joint pain and swelling
- Diarrhea
Dosage and Administration
- Abirapro 250mg Tablet should be taken on an empty stomach, at least 2 hours before or 1 hour after food.
- Taking it with food may increase the blood levels of Abirapro 250mg Tablet, which may cause side effects.
- You should take it exactly as your doctor has advised.
- Your doctor will decide the dose and duration of Abirapro 250mg Tablet.
Mechanism of action
Abirapro works by blocking an enzyme (CYP17) involved in producing androgens (male hormones) like testosterone.
Prostate cancer cells rely on these hormones to grow, so reducing them slows or stops the cancer's progression.
Safety Advice
Avoid the intake of alcohol when the treatment is going on. Consult the doctor before taking this medication.
Abirapro 250mg Tablet should not be consumed by pregnant women, as it can harm the foetus. Women who are pregnant or who may become pregnant should not touch this medication without gloves. Both men and women should use reliable birth control throughout treatment to prevent pregnancy.
Abirapro 250mg Tablet is not indicated to be use in breastfeeding women. Inform your doctor if you are breastfeeding before starting treatment with this medication.
Abirapro 250mg Tablet is unlikely to interfere with driving or operating machinery.
Share your medical history with the doctor in case of any kidney problems.
Do not consume Abirapro 250 mg tablet in case of liver disease. Consult your doctor as it can cause liver toxicity.
Missed Doses
Try not to miss any dose of Abirapro 250 mg tablet. In case you missed it, do not overdose. Follow the regular schedule and consult your doctor immediately.
FAQs
Abirapro is an anti-cancer hormonal treatment drug.
It is not administered for curing cancer but enables prolonging and improving life by curbing the spread of cancer in male patients suffering from prostate cancer.
References
- Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014). Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The oncologist, 19(12), 1231-1240 - https://pubmed.ncbi.nlm.nih.gov/25361624/
- Cancer Research UK. 2024. Together we will beat cancer. 2024. Steroids (dexamethasone, prednisolone,methylprednisolone and hydrocortisone). https://www.cancerresearchuk.org/about-cancer/treatment/drugs/steroids - https://www.cancerresearchuk.org/about-cancer/treatment/drugs/steroids
- Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., ... & Chi, K. N. (2017). Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine, 377(4), 352-360 - https://pubmed.ncbi.nlm.nih.gov/28578607/
- Jena, B. R., Panda, S. P., Kulandaivelu, U., Alavala, R. R., Rao, G. K., Swain, S., ... & Ghose, D. (2021). AQbD driven development of an RP-HPLC method for the quantitation of abiraterone acetate for its pharmaceutical formulations in the presence of degradants. Turkish journal of pharmaceutical sciences, 18(6),
- 718. - https://pubmed.ncbi.nlm.nih.gov/34978401/
- Kaler, J., Hussain, A., Haque, A., Naveed, H., & Patel, S. (2020). A comprehensive review of pharmaceutical and surgical interventions of prostate cancer. Cureus, 12(11) - https://pmc.ncbi.nlm.nih.gov/articles/PMC7681941/
- Kumar, S., Joshi, A., Takke, A., Varghese, D., Pathak, S., Noronha, V., ... & Gota, V. (2025). Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis. Indian Journal of Medical and Paediatric Oncology.
- National cancer institute. 2023. Abiraterone acetate. https://www.cancer.gov/about-cancer/treatment/drugs/abirateroneacetate.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
